28 May 2024
Annual General Meeting of Ipsen S.A. held on 28 May 2024
27 May 2022
ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different…
08 February 2024
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
18 November 2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in…
13 February 2023
Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line…
Explore more press releases
Topics
Period
recent search
Showing: 1 – 05 of 150 Press Releases
01 December 2025
01 December 2025
Ipsen mourns the passing of Henri Beaufour, a founding family Board member
PARIS, FRANCE, 1 DECEMBER 2025 – It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025.
07 November 2025
07 November 2025
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Paris, France – 7 November, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new Primary Biliary Cholangitis (PBC) data with IQIRVO® from the ELATIVE trial1, 2 will be presented in two late-breaking sessions, at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD).
22 October 2025
22 October 2025
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
PARIS, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.
22 October 2025
22 October 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics,…
22 September 2025
22 September 2025
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200…
Your dedicated contacts
-
Media Relations
-
